SABCS 2023: HER2CLIMB-02 Trial in Metastatic HER2-Positive Breast Cancer
Posted: 12/20/2023 | By: Chase Doyle

The HER2CLIMB-02 trial, results of which were presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS01-10), examined a combination of two HER2-targeted drugs in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Question 1 of 5

Tucatinib, a small-molecule inhibitor of HER2, shows particular activity in which group of patients?

Choose 1